What are the indications for mupirocin?

Indications for Mupirocin

Mupirocin 2% ointment is FDA-approved for topical treatment of impetigo caused by Staphylococcus aureus and Streptococcus pyogenes, and is also guideline-recommended for other minor superficial skin infections, secondarily infected wounds, and MRSA nasal decolonization in specific clinical scenarios. 1, 2

FDA-Approved Primary Indication

• Impetigo: Mupirocin 2% ointment is specifically indicated for impetigo due to S. aureus (including MRSA) and S. pyogenes 1, 2
• Applied 2-3 times daily for 5-10 days 2, 3
• Minimum age: 2 months (not approved for neonates younger than 2 months) 4

Guideline-Supported Clinical Uses

Minor Superficial Skin Infections

• Secondarily infected skin lesions including infected eczema, ulcers, or lacerations 2
• Small cutaneous abscesses as adjunctive therapy after incision and drainage (I&D remains primary treatment) 2
• Infected wounds and other localized superficial infections caused by susceptible staphylococci and streptococci 2, 3

MRSA Nasal Decolonization

For recurrent skin and soft tissue infections (SSTIs):

• Use when a patient develops recurrent SSTI despite optimizing wound care and hygiene measures 3
• Apply intranasally twice daily for 5-10 days 3, 2
• Can reduce recurrences by approximately 50% when applied the first 5 days of each month 2
• Most effective when combined with chlorhexidine body washes 2, 3

For outbreak control and surgical prophylaxis:

• Eradicates MRSA nasal carriage when applied twice daily for 5-7 days 2
• In cardiac surgery patients, apply to each nostril starting at least 48 hours before surgery for total of 5-7 days to significantly reduce postoperative MRSA infections 2

For household transmission:

• Consider decolonization when ongoing transmission occurs among household members despite hygiene measures 3
• Symptomatic contacts should be treated for active infection first, then consider decolonization 3

Important Limitations and When NOT to Use Mupirocin

Infections Requiring Systemic Antibiotics Instead

• Deep soft tissue infections or complicated SSTIs in hospitalized patients 2
• Extensive infections with systemic signs (fever, extensive cellulitis) 2
• Large furuncles and all carbuncles require I&D as primary treatment; systemic antibiotics indicated if extensive surrounding cellulitis or fever present 2
• Bacteremia, endocarditis, or endovascular infections 3
• Immunocompromised patients with significant infections 2

Age Restrictions

• Contraindicated in neonates under 2 months of age due to lack of safety data 4
• For neonatal skin infections, consult pediatric infectious disease for weight-based systemic antibiotics (nafcillin, cefazolin for MSSA; vancomycin for MRSA) 4

Resistance Concerns

• Avoid prolonged or indiscriminate use to prevent development of resistance 2, 5
• High-level mupirocin resistance (MIC >512 µg/mL) is associated with treatment failure 2
• Screening cultures prior to decolonization are not routinely recommended if at least one prior infection was documented as MRSA 3
• Surveillance cultures following decolonization are not routinely recommended in absence of active infection 3

Clinical Algorithm for Mupirocin Use

Step 1: Assess infection severity and extent

• Localized, superficial, no systemic signs → Consider mupirocin 2
• Deep, extensive, or systemic signs → Systemic antibiotics required 2

Step 2: Determine if drainage needed

• Purulent collection present → I&D is primary treatment; mupirocin may be adjunctive 2
• No collection → Mupirocin appropriate for susceptible organisms 2

Step 3: For recurrent infections

• First optimize hygiene and wound care 3
• If recurrences persist → Decolonization with intranasal mupirocin + chlorhexidine washes 3, 2
• For particularly persistent furunculosis → Consider clindamycin 150 mg daily for 3 months (decreases infections by ~80%) 2

Step 4: Monitor response

• If no improvement within 5 days → Reassess and consider systemic antibiotics 2, 6
• Obtain cultures if worsening to guide therapy 4